SEC Form 144 filed by 9 Meters Biopharma Inc.
| Form 144 Filer Information |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144
NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 | |
FORM 144 |
144: Filer Information
| Filer CIK | 0001301715 |
| Filer CCC | XXXXXXXX |
| Is this a LIVE or TEST Filing? |  LIVE
 TEST
|
Submission Contact Information | |
| Name | |
| Phone | |
| E-Mail Address |
144: Issuer Information
| Name of Issuer | 9 METERS BIOPHARMA, INC. |
| SEC File Number | 001-37797 |
| Address of Issuer | 4509 CREEDMOOR ROAD SUITE 600 RALEIGH NORTH CAROLINA 27612 |
| Phone | 919-275-1933 |
| Name of Person for Whose Account the Securities are To Be Sold | Sirgo Mark A |
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account
the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given
as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales
for the account of the person filing this notice.
| |
| Relationship to Issuer | Director |
144: Securities Information
| Title of the Class of Securities To Be Sold | Name and Address of the Broker | Number of Shares or Other Units To Be Sold | Aggregate Market Value | Number of Shares or Other Units Outstanding | Approximate Date of Sale | Name the Securities Exchange | |||
|---|---|---|---|---|---|---|---|---|---|
| Common | Fidelity Brokerage Services LLC Get the next $NMTR alert in real time by email245 Summer Street Boston Chat with this insightSave time and jump to the most important pieces. Recent Analyst Ratings for |
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/8/2021 | $5.00 | Outperform | BMO Capital Markets |
9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022
Positive final results from the vurolenatide Phase 2 VIBRANT study in short bowel syndrome (SBS) reaffirmed the efficacy and safety of vurolenatide and determined the Phase 3 dose and regimenClinical plans and activities are underway including site and patient recruitment to facilitate Phase 3 study initiation upon protocol finalization with FDA this quarterRALEIGH, NC / ACCESSWIRE / November 8, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the third quarter ended Septembe
9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022
Positive preliminary results from Phase 2 VIBRANT study of vurolenatide in short bowel syndrome announcedVurolenatide End-of-Phase 2 meeting with FDA on track for 3QCash balance as of June 30, 2022 of $29.5 million; additional $20 million from previously announced July debt financing extends cash runway into 4Q 2023RALEIGH, NC / ACCESSWIRE / August 15, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the second quarter ended June 30, 2022.John Temperato, President & Chief Exe
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022
On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in JuneCash balance as of March 31, 2022, of $37.2 million is expected to fund ongoing clinical programs and business operations into Q2 2023RALEIGH, NC / ACCESSWIRE / May 16, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the first quarter ended March 31, 2022.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "This is
SEC Form 25-NSE filed by 9 Meters Biopharma Inc.
25-NSE - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
SEC Form 144 filed by 9 Meters Biopharma Inc.
144 - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
9 Meters Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation, Bankruptcy or Receivership, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits
8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately.Mark Sirgo, Chairman of the Board of 9 Meters, stated, "On behalf of the Board of Directors, I want to thank John for his service and dedication to the Company." The Board of Directors has appointed Bethany Sensenig, Chief Financial Officer of 9 Meters, to serve as interim Chief Executive Officer in addition to her current responsibiliti
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023
RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "We are enthusiastic about the potential of vurolenatide and NM-136 to deliver value to patients. We are exploring options to fund further advancement of these assets, including financing and other strategic alternatives."Clinical Development and Business HighlightsPresentations on vurolenatide and SBS at ASPEN 2
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity
RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment of obesity. Based on the response, the Company currently plans to submit an IND to the FDA for this indication in the second half of 2023 based on the completion of the preclinical program. An approved IND is a prerequisite for conducting Phase 1 clinical studies of NM-136
Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer
Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,
9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experienceRALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today the Company has appointed Bethany Sensenig, MBA, CMA, as Chief Financial Officer."We're very pleased to have Ms. Sensenig join the 9 Meters team as Chief Financial Officer with over twenty years of business and strategic financial leadership experience at both early-stage and large biotechnology companies," said John Temperato, President & Chief
9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications
RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Sarah Liu, MBA, as Chief Commercial Officer and Al Medwar, MBA, as Senior Vice President, Investor Relations & Corporate Communications."We are very excited to have such talented individuals, each with lengthy and accomplished pharmaceutical and biotech backgrounds, join the 9 Meters team during this critical time of growth for our company," said John Temperato, President & Chief Executive Officer of 9 Meters Biopharma. "Ms. Liu's
SEC Form SC 13G/A filed by 9 Meters Biopharma Inc. (Amendment)
SC 13G/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
SEC Form SC 13G/A filed by 9 Meters Biopharma Inc. (Amendment)
SC 13G/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
SEC Form SC 13G filed by 9 Meters Biopharma Inc.
SC 13G - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)
BMO Capital Markets initiated coverage on 9 Meters Biopharma with a new price target
BMO Capital Markets initiated coverage of 9 Meters Biopharma with a rating of Outperform and set a new price target of $5.00
Citigroup initiated coverage on 9 Meters Biopharma with a new price target
Citigroup initiated coverage of 9 Meters Biopharma with a rating of Buy and set a new price target of $3.00
Brookline Capital resumed coverage on 9 Meters Biopharma with a new price target
Brookline Capital resumed coverage of 9 Meters Biopharma with a rating of Buy and set a new price target of $6.00
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock rose 36.8% to $0.1 during Tuesday's after-market session. At the close, 9 Meters Biopharma's trading volume reached 4.7 million shares. This is 1095.7% of its average volume over the last 100 days. The company's market cap stands at $1.4 million. ViewRay (NASDAQ:VRAY) stock moved upwards by 11.99% to $0.03. Trading volume for this security closed at 19.2 million, accounting for 150.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.1 million. Plus Therapeutics (NASDAQ:PSTV) stock increased by 10.36% to $2.45. The company's market cap stands at $6.1 million. PAVmed (NASDAQ:PAVM) sha
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Bullfrog AI Hldgs (NASDAQ:BFRG) shares moved upwards by 33.8% to $4.63 during Tuesday's regular session. Trading volume for Bullfrog AI Hldgs's stock is 42.6 million as of 13:30 EST. This is 8458.3% of its average full-day volume over the last 100 days. The company's market cap stands at $28.2 million. Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock rose 32.66% to $19.82. Trading volume for Kiniksa Pharmaceuticals's stock is 3.0 million as of 13:30 EST. This is 719.4% of its average full-day volume over the last 100 days. The company's market cap stands at $1.3 billion. As per the press release, Q2 earnings came out today. Galecto (NASDAQ:GLTO) shares rose 28.51% to $3.02. As of 13:30
Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Aurora Acquisition Corp. (NASDAQ:AURC) shares jumped 192% to $30.54. Inpixon (NASDAQ:INPX) gained 117% to $0.33 after the company agreed to merge with XTI Aircraft Company. Electra Battery Materials Corporation (NASDAQ:ELBM) shares shot up 71.5% to $2.11 after jumping 22% on Monday. Electra Battery Materials said its battery grade cobalt supply agreement with LG Energy Solution has been extended and expanded from terms initially announced in Sept. 2022. Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) shares gained 35.3% to $4.68 after the company announced US patent for novel prodrugs of mebendazole and their use in treating cancer. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) climb
SEC Form 4 filed by Sensenig Bethany
4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)
SEC Form 4 filed by Sirgo Mark A
4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)
SEC Form 4 filed by Rice Yehuda Michael
4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)